These results, coupled with the preclinical finding that CCK administration increases the incidence of pancreatitis in rodents [57], suggest that CCK agonists are not appealing candidates for monotherapy of obesity, although their efficacy in combined treatments cannot be ruled out. The gene discussed is CCK; the disease is Obesity.